ChinaAMC Hang Seng Biotech ETF (03069.HK) Falls 2.96% Intraday as Duality's HER2 ADC Meets Phase III Endpoint but Shares Plunge 31%

NewTimeSpace News: As of 15:24 on October 27, the ChinaAMC Hang Seng Biotech ETF (03069.HK) fell 2.96% to a latest price of HK$14.100. The ETF has traded 7.3518 million units so far today for a turnover of HK$105 million at an average price of HK$14.285, with a turnover rate of 3.33%. It is down 3.23% so far this week. Its current net asset value per unit is HK$14.5286, and its assets under management stand at HK$3.211 billion.

(Note on scope: the net asset value per unit and assets under management are as of October 26, 2026; the week-to-date change is measured against the closing price of HK$14.570 on October 23.)

On the news front, Duality Biotherapeutics-B (09606) announced on October 26 that DB-1303, a HER2 antibody-drug conjugate (ADC) developed with BioNTech, met the primary endpoint in the global Phase III DYNASTY-Breast02 trial, though its overall benefit remains to be assessed; the stock plunged 31.05% on October 27, among the day's biggest decliners, and is a constituent of the Hang Seng Biotech Index. Dragged by the move, the index opened lower on October 27 and briefly lost the 14,000 level in early trade, narrowing its loss to 1.38% by 10:23 before widening to 2.48% in the afternoon. Other constituents also fell: Ascentage Pharma dropped 6.70%, Kelun-Biotech 5.96%, 3SBio 5.10%, CSPC Pharmaceutical 4.25%, Akeso 3.63%, Sino Biopharmaceutical 3.26%, Hansoh Pharma 3.10% and BeiGene 3.03%, while GenScript Biotech, Sinopharm and Weigao rose against the trend.

The ChinaAMC Hang Seng Biotech ETF (03069.HK) is a passively managed exchange-traded fund under China Asset Management (Hong Kong), with the investment objective of closely tracking the performance of the Hang Seng Biotech Index. Compiled by Hang Seng Indexes Company on a net total return basis, the index reflects the overall performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound trading, including pre-revenue companies listed under Chapter 18A of the Listing Rules; its constituents span the Hang Seng Industry Classification System sub-sectors of biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical devices and supplies, weighted by freefloat-adjusted market capitalisation with a 10% cap on any single constituent.

Zhongtai Securities noted that the concentrated third-quarter reporting season is a key window for testing CXO prosperity, with notable divergence within the sector, and that major overseas clinical data and innovative drug BD deals are important catalysts; leading companies' order delivery is improving, but the market's requirements for converting orders into profit have risen, making short-term sector performance sensitive to risk appetite, so investors are better off focusing on CXO leaders with solid order books and a clear path to earnings improvement.